Sensitive Enzyme Immunoassay for Measuring Plasma and Intracellular Nevirapine Levels in Human Immunodeficiency Virus-Infected Patients

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 104-109

  Azoulay, Stéphane ^a   Nevers, Marie Claire ^c   Créminon, Christophe ^c   Heripret, Laurence ^b   Durant, Jacques ^b   Dellamonica, Pierre ^b   Grassi, Jacques ^c   Guedj, Roger ^a   Duval, Danièle ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Institut National de la Recherche Agronomique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ANTIGEN; CELL EXTRACT; KEYHOLE LIMPET HEMOCYANIN; NEVIRAPINE; POLYCLONAL ANTIBODY; REAGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRACER;

ACCURACY; ADULT; ARTICLE; CELL CULTURE; CELL LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LYMPHOBLASTOID CELL; MALE; MEASUREMENT; MICROTITER PLATE ASSAY; PATIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RABBIT; SENSITIVITY ANALYSIS; T LYMPHOBLAST;

ADULT; ANIMALS; ANTI-HIV AGENTS; CELLS, CULTURED; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOENZYME TECHNIQUES; INDICATORS AND REAGENTS; LEUKOCYTES; MALE; MIDDLE AGED; NEVIRAPINE; RABBITS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TEMPERATURE;

EID: 0347992033     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.104-109.2004     Document Type: Article

References (26)

1. Akeb, F., B. Ferrua, C. Creminon, C. Roptin, J. Grassi, M. C. Nevers, R. Guedj, R. Garraffo, and D. Duval. 2002. Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA. J. Immunol. Methods 263:1-9.
2. Boffito, M., K. Sciole, R. Raiteri, S. Bonora, P. G. Hoggard, D. J. Back, and G. Di Perri. 2002. Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens. Drug Metab. Dispos. 30:859-860.
3. Chaillou, S., J. Durant, R. Garraffo, E. Georgenthum, C. Roptin, B. Dunais, V. Mondain, P. M. Roger, and P. Dellamonica. 2002. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin. Trials 3:493-501.
4. Cheeseman, S. H., S. E. Hattox, M. M. McLaughlin, R. A. Koup, C. Andrews, C. A. Bova, J. W. Pav, T. Roy, J. L. Sullivan, and J. J. Keirns. 1993. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob. Agents Chemother. 37:178-182.
5. de Jong, M. D., S. Vella, A. Carr, C. A. Boucher, A. Imrie, M. French, J. Hoy, S. Sorice, S. Pauluzzi, F. Chiodo, G. J. Weverling, M. E. van der Ende, P. J. Frissen, H. M. Weigel, R. H. Kauffmann, J. M. Lange, R. Yoon, M. Moroni, E. Hoenderdos, G. Leitz, D. A. Cooper, D. Hall, and P. Reiss. 1997. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J. Infect. Dis. 175:966-970.
6. Fan, B., and J. T. Stewart. 2002. Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J. Pharm. Biomed. Anal. 28:903-908.
7. Grassi, J., Y. Frobert, P. Pradelles, F. Chercuitte, D. Gruaz, J. M. Dayer, and P. E. Poubelle. 1989. Production of monoclonal antibodies against interleukin-1 alpha and -1 beta. Development of two enzyme immunometric assays (EIA) using acetylcholinesterase and their application to biological media. J. Immunol. Methods 123:193-210.
8. Havlir, D., S. H. Cheeseman, M. McLaughlin, R. Murphy, A. Erice, S. A. Spector, T. C. Greenough, J. L. Sullivan, D. Hall, M. Myers, M. Lamson, and D. D. Richman. 1995. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171:537-545.
9. Hoggard, P. G., and A. Owen. 2003. The mechanisms that control intracellular penetration of the HIV protease inhibitors. J. Antimicrob. Chemother. 51:493-496.
10. Hollanders, R. M., E. W. van Ewijk-Beneken Kolmer, D. M. Burger, E. W. Wuis, P. P. Koopmans, and Y. A. Hekster. 2000. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J. Chromatogr. B 744:65-71.
11. Jones, K., P. G. Bray, S. H. Khoo, R. A. Davey, E. R. Meaden, S. A. Ward, and D. J. Back. 2001. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15:1353-1358.
12. Jones, K., P. G. Hoggard, S. D. Sales, S. Khoo, R. Davey, and D. J. Back. 2001. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15:675-681.
13. Khoo, S. H., P. G. Hoggard, I. Williams, E. R. Meaden, P. Newton, E. G. Wilkins, A. Smith, J. F. Tjia, J. Lloyd, K. Jones, N. Beeching, P. Carey, B. Peters, and D. J. Back. 2002. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob. Agents Chemother. 46:3228-3235.
14. Laurito, T. L., V. Santagada, G. Caliendo, C. H. Oliveira, R. E. Barrientos-Astigarraga, and G. De Nucci. 2002. Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J. Mass Spectrom. 37:434-441.
15. Livingstone, W. J., M. Moore, D. Innes, J. E. Bell, and P. Simmonds. 1996. Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group. Lancet 348:649-654.
16. Montaner, J., and R. Murphy. 1996. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp. Opin. Investig. Drugs 5:1183-1199.
17. Rezk, N. L., R. R. Tidwell, and A. D. Kashuba. 2002. Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. J. Chromatogr. B 774:79-88.
18. Riska, P., M. Lamson, T. MacGregor, J. Sabo, S. Hattox, J. Pav, and J. Keirns. 1999. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 27:895-901.
19. Sawchuk, R. J., and Z. Yang. 1999. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv. Drug Deliv. Rev. 39:5-31.
20. Smith, P. F., R. DiCenzo, and G. D. Morse. 2001. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40:893-905.
21. Stormer, E., L. L. von Moltke, M. D. Perloff, and D. J. Greenblatt. 2002. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19:1038-1045.
22. van Heeswijk, R. P., R. M. Hoetelmans, P. L. Meenhorst, J. W. Mulder, and J. H. Beijnen. 1998. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 713:395-399.
23. van Heeswijk, R. P., A. I. Veldkamp, J. W. Mulder, P. L. Meenhorst, F. W. Wit, J. M. Lange, S. A. Danner, N. A. Foudraine, M. O. Kwakkelstein, P. Reiss, J. H. Beijnen, and R. M. Hoetelmans. 2000. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 14:F77-F82.
24. Villani, P., M. Feroggio, L. Gianelli, A. Bartoli, M. Montagna, R. Maserati, and M. B. Regazzi. 2001. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay. Ther. Drug Monit. 23:380-388.
25. Wijnholds, J., C. A. Mol, L. van Deemter, M. de Haas, G. L. Scheffer, F. Baas, J. H. Beijnen, R. J. Scheper, S. Hatse, E. De Clercq, J. Balzarini, and P. Borst. 2000. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 97:7476-7481.
26. + monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 76:707-716.